These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17083507)

  • 41. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
    Mehta R; Parameswaran R; Shapiro AD
    Haemophilia; 2006 Dec; 12 Suppl 6():54-61. PubMed ID: 17123395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of incidence of inhibitors in patients with haemophilia.
    van der Bom JG; ter Avest P; Van den Berg HM; Psaty BM; Weiss NS
    Haemophilia; 2009 May; 15(3):707-11. PubMed ID: 19432923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR; Casaña P; Cabrera N; Haya S; Cortina V; Aznar JA
    Haemophilia; 2007 Mar; 13(2):206-8. PubMed ID: 17286776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiology of inhibitors in haemophilia A.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Güngör T; Kornhuber B
    Vox Sang; 1996; 70 Suppl 1():2-8. PubMed ID: 8869461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
    Franchini M; Tagliaferri A; Mengoli C; Cruciani M
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
    Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
    Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitors in previously treated patients: a review of the literature.
    Kempton CL
    Haemophilia; 2010 May; 16(102):61-5. PubMed ID: 20536987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
    Fischer K; Lewandowski D; Marijke van den Berg H; Janssen MP
    Haemophilia; 2012 May; 18(3):e241-6. PubMed ID: 22044445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003.
    Blatny J; Komrska V; Blazek B; Penka M; Ovesna P;
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):673-8. PubMed ID: 25886834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
    van den Berg HM
    Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
    Hu G; Guo D; Key NS; Conti-Fine BM
    Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J; Pavlova A
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.